Cervical cancer is claimed to be a malignant neoplasm of the cervix uteri or cervical region.Well, study authors from the Ireland Cancer Center of University Hospitals (UH) Case Medical Center have apparently made new discoveries which could result in a new quality of care for patients suffering from locally advanced stage of cervical cancer.
The phase one study supposedly discovered that a novel chemotherapy medicine, Triapine, seemed to be well tolerated in grouping with standard-of-care cisplatin chemotherapy and radiation treatment among women having cervical cancer. This course of therapy appeared to deliver both noteworthy drops in cancer disease as well as cancer control.
Charles Kunos, MD, Primary Investigator of the study, Director of Gynecologic Radiation Oncology at UH Case Medical Center and Assistant Professor at Case Western Reserve University School of Medicine, commented, “This new drug, which suppresses tumor growth, shows a great deal of promise for cervical cancer patients who are at high risk for relapse and cancer-related death. In this ten-patient study, a 100% complete response rate was observed and no disease progression was documented through 18 months of median follow-up.”
In the study, patients were believed to have been treated three times a week with Triapine in amalgamation with weekly cisplatin treatment and every day pelvic radiation therapy over duration of around five weeks. A phase two follow-up study is apparently continuing at the Ireland Cancer Center.
The study was published in the Clinical Cancer Research.